The symptoms that change — and the ones that don't

You spent your 20s managing irregular cycles, acne, and the exhausting hair situation. Then somewhere in your 30s, things started shifting. Cycles became more regular. Skin cleared. The diagnosis still sits in your medical file, but you feel less like a textbook case.

This is a recognized pattern. Androgens — testosterone, DHEA-S, androstenedione — naturally decline in women with each decade of adult life, and women with PCOS follow the same trajectory. By the mid-30s to early 40s, androgen levels in many women with PCOS begin to converge toward non-PCOS levels. Skin and hair symptoms driven by androgen excess often improve noticeably, sometimes substantially.

8–13%
Prevalence of PCOS in reproductive-age women globally — making it the most common endocrine disorder in women, yet most long-term outcome data focuses only on the reproductive years
Later
Age of natural menopause in women with PCOS, per April 2026 Acta Obstetricia et Gynecologica Scandinavica — attributed to higher antral follicle count and larger ovarian reserve
2–4x
Elevated lifetime risk of type 2 diabetes in women with PCOS compared to the general female population — a metabolic risk that persists regardless of cycle regularity or androgen normalization

The 2026 finding — PCOS may actually protect against early menopause

This is the part that's counterintuitive. PCOS is associated with polycystic-appearing ovaries — multiple small follicles that don't complete ovulation. That larger pool of follicles means a bigger ovarian reserve. And a bigger reserve means more follicles available as the ovary ages toward menopause.

A study published April 8, 2026 in Acta Obstetricia et Gynecologica Scandinavica found that women with PCOS transition to menopause later than women without PCOS. The authors note that this longer exposure to natural estrogen may confer health benefits — lower bone loss rates, potentially lower cardiovascular risk from early estrogen depletion. The finding doesn't make PCOS beneficial overall, but it complicates the picture in ways that matter for long-term planning.

Research note

A 2020 longitudinal cohort study by Louwers et al. followed women with PCOS for over 20 years and found that while reproductive symptoms improved with age, metabolic markers — fasting glucose, triglycerides, waist circumference — worsened in a significant proportion of participants who did not maintain active lifestyle interventions. The conclusion: symptom improvement does not equal metabolic resolution. Annual metabolic screening remains relevant well into the 40s and 50s for women with PCOS.

What to monitor — and what actually requires ongoing attention

The metabolic picture is where age changes the risk calculus. Insulin resistance, which underlies most PCOS in the hyperandrogenic phenotype, doesn't self-resolve. In the 40s, it intersects with perimenopause-related metabolic changes — declining estrogen increases visceral fat and insulin sensitivity further worsens. Women with PCOS entering perimenopause may find weight management harder and blood sugar more volatile than they experienced in their 30s.

The practical priorities from 35 onward: annual fasting glucose and HbA1c (not just "normal" — the optimal range for PCOS is fasting glucose under 95, not just under the diabetic threshold), blood pressure, lipid panel, and a conversation about cardiovascular risk stratification. These aren't alarmist recommendations — they're the standard of care that too often gets dropped once the PCOS conversation shifts from fertility to "you seem fine now."

The monitoring conversation to have

Ask your doctor specifically for fasting insulin alongside fasting glucose — standard blood panels often don't include it. A normal fasting glucose with elevated insulin is a sign of early insulin resistance that would otherwise be missed. HOMA-IR (calculated from both values) gives a clearer picture of metabolic status in PCOS than glucose alone.

PCOS and perimenopause — a collision that's under-researched

Perimenopause symptoms can be harder to distinguish in women with PCOS. Irregular cycles are already the baseline. Hot flashes and sleep disruption may be attributed to other causes. The hormonal picture is more complicated because PCOS involves androgen excess on top of the estrogen fluctuation of perimenopause.

The honest answer: this intersection is genuinely under-researched. Most perimenopause clinical guidance doesn't account for PCOS comorbidity. If you have PCOS and are approaching your mid-40s, seeking care from a gynecologist or endocrinologist who specifically knows both conditions isn't overcautious — it's appropriate.

🩺

What to bring up at your next appointment

Request annual screening for: fasting glucose, fasting insulin (not just glucose), HbA1c, lipid panel, and blood pressure. If you're approaching perimenopause, ask specifically about how PCOS may affect your transition and whether your provider has experience managing this overlap. Sleep apnea — more common in PCOS — should also be on the radar; it's underdiagnosed in women and worsens metabolic outcomes.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

  1. Joham AE, et al. Polycystic ovary syndrome and menopause: a systematic review. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(4). Published online April 8, 2026.
  2. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Therapeutic Advances in Reproductive Health. 2020;14. doi:10.1177/2633494120911038
  3. Teede HJ, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction. 2018;33(9):1602–1618. doi:10.1093/humrep/dey256
  4. Moran LJ, et al. Long-term metabolic outcomes of PCOS. Journal of Clinical Endocrinology & Metabolism. 2019;104(8):3325–3337. doi:10.1210/jc.2018-01753